Updated:
Vetio Animal Health
Vetio Animal Health, a Swedencare subsidiary, is a North American CDMO focused on veterinary pharmaceuticals, pet supplements, and topical products.
Vetio Animal Health
Vetio Animal Health was formed in November 2018, when Tropichem Research Labs unified its businesses under the Vetio name after acquiring TetraGenx earlier that year. The firm is a wholly-owned subsidiary of Swedencare AB (publ), which is listed on Nasdaq First North Growth Market in Stockholm and generated roughly 500 employees across eight countries as of its acquisition announcement. Vetio operates as a contract development and manufacturing organization (CDMO) focused exclusively on animal health. Its capabilities span product development, technical services, contract manufacturing, and analytical services — covering tablets, soft chews, spot-ons, dermatology topicals, and pharmaceutical processing such as granulation, coating, hot melt, and taste masking. The firm serves clients across the United States and Canada, with confirmed facilities in St. Louis (HQ), Jupiter, Florida, and Montreal, Quebec. The firm does not disclose AUM, deployment figures, or team size. It maintains no publicly listed investment professionals. Vetio's operations are integrated with Swedencare's broader portfolio, which includes brands such as NaturVet, nutravet, and ProDen PlaqueOff. December 2021: Vetio completed a 35,000-square-foot expansion of its Jupiter site for supplement manufacturing, R&D lab, and warehouse space ahead of schedule. Vetio's structural distinction lies in its pure-play CDMO model dedicated solely to animal health — a narrower focus than most contract manufacturers, which typically also serve human pharma or consumer goods. Its ownership by a publicly-traded Swedish parent (Swedencare) creates a governance layer uncommon among privately-owned CDMOs, combining public reporting obligations with operational autonomy in North America.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
St. Louis
Corporate office
St. Louis, MO, United States
Additional offices
Jupiter, FL, United States · Montreal, QC, Canada
Sector focus
Frequently asked questions
Who owns Vetio Animal Health?
Vetio is a wholly-owned subsidiary of Swedencare AB (publ), a pet healthcare company listed on Nasdaq First North Growth Market in Stockholm, Sweden. Swedencare acquired Vetio (then operating as Tropichem) in 2021, according to the firm's website. The parent company's product portfolio includes brands such as NaturVet, nutravet, and ProDen PlaqueOff.
What is Vetio's core business?
Vetio operates as a contract development and manufacturing organization (CDMO) exclusively for animal health products. It offers services from product development and formulation through to commercial manufacturing, analytical testing, and technical transfers. The firm's finished dose forms include tablets, soft chews, spot-ons, and dermatology topicals.
Does Vetio invest in external companies or funds?
No. Vetio is a CDMO, not an investment firm. It does not deploy capital into third-party funds or direct investments. The firm's financial structure is tied to its parent Swedencare, which is publicly traded and reports consolidated financials.
Where are Vetio's facilities located?
Vetio's headquarters is in St. Louis, Missouri. It operates additional facilities in Jupiter, Florida (focused on supplement manufacturing, R&D, and warehousing) and Montreal, Quebec (liquid and semi-solid manufacturing). The Jupiter site underwent a 35,000-square-foot expansion completed in December 2021.
What is Vetio's patent situation for soft chews?
In June 2022, Vetio received an Intention to Grant from the European Patent Office and a Notice of Allowance from the US Patent Office for its starch-free soft chew technology for veterinary applications. This indicates the firm has proprietary intellectual property in animal health dosage forms.
Does Vetio work with cannabis-based veterinary products?
Yes. In February 2020, Vetio (then operating as Tropichem) was awarded a Cannabis Research License from Health Canada and began development of cannabis-based veterinary drug products at its Montreal facility, per the firm's website. The current status of that program is not publicly updated.
Is Vetio a family office?
No. Vetio is a CDMO subsidiary of a publicly-traded company, not a family office. It does not manage capital for wealthy individuals or families. Its AUM and deployment figures are undisclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: